5-HT3 Receptor Modulator Salts for Efficacy and Side Effects

The patent applies parameter changes by modifying the chemical structure of 5-HT3 receptor modulators through creating new compounds with specific molecular configurations (formula I structures with varying R1-R6 substituents). This structural parameter modification aims to optimize the balance between therapeutic efficacy and side effect profile, resolving the contradiction by finding molecular parameters that maximize benefit while minimizing harm.

The patent employs composite materials by developing pharmaceutical compositions that combine the novel 5-HT3 receptor modulator compounds with pharmaceutically acceptable excipients and carriers. These composite formulations are designed to enhance therapeutic effectiveness while reducing adverse effects, addressing the contradiction between reliability and harmful factors through optimized material composition.

The patent applies universality by developing 5-HT3 receptor modulator compounds that can treat multiple conditions including irritable bowel syndrome, chemotherapy-induced nausea, postoperative nausea, and carcinoid syndrome. The novel compounds demonstrate broad therapeutic coverage across different gastrointestinal and neurological disorders, resolving the contradiction between efficacy and adaptability by creating multi-functional pharmaceutical agents.

The patent uses parameter changes by systematically varying the molecular structure parameters of the 5-HT3 modulators (different substituent groups at R1-R6 positions) to optimize activity across multiple disease indications. This structural parameter optimization enables the compounds to maintain high efficacy while adapting to treat diverse conditions, addressing the contradiction between reliability and versatility.

The patent applies segmentation by dividing the complex molecular structure into modular components with defined substituent positions (R1-R6 groups) that can be independently optimized. This segmented structural approach allows for systematic development of multiple compound variants while using common core structures and synthetic pathways, reducing manufacturing complexity despite improved efficacy requirements.

The patent resolves the contradiction between efficacy and manufacturing complexity by making controlled parameter changes to the molecular structure. By varying substituent parameters at specific positions while maintaining the core 5-HT3 modulator framework, the patent achieves improved therapeutic efficacy through optimized molecular parameters without fundamentally redesigning the entire synthesis pathway, thus managing manufacturing complexity.